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Abstract
Diversification of antiretroviral factors during host evolution has erected formidable barriers to cross-species retrovirus
transmission. This phenomenon likely protects humans from infection by many modern retroviruses, but it has also
impaired the development of primate models of HIV-1 infection. Indeed, rhesus macaques are resistant to HIV-1, in part due
to restriction imposed by the TRIM5a protein (rhTRIM5a). Initially, we attempted to derive rhTRIM5a-resistant HIV-1 strains
using two strategies. First, HIV-1 was passaged in engineered human cells expressing rhTRIM5a. Second, a library of
randomly mutagenized capsid protein (CA) sequences was screened for mutations that reduced rhTRIM5a sensitivity. Both
approaches identified several individual mutations in CA that reduced rhTRIM5a sensitivity. However, neither approach
yielded mutants that were fully resistant, perhaps because the locations of the mutations suggested that TRIM5a recognizes
multiple determinants on the capsid surface. Moreover, even though additive effects of various CA mutations on HIV-1
resistance to rhTRIM5a were observed, combinations that gave full resistance were highly detrimental to fitness. Therefore,
we employed an ‘assisted evolution’ approach in which individual CA mutations that reduced rhTRIM5a sensitivity without
fitness penalties were randomly assorted in a library of viral clones containing synthetic CA sequences. Subsequent passage
of the viral library in rhTRIM5a-expressing cells resulted in the selection of individual viral species that were fully fit and
resistant to rhTRIM5a. These viruses encoded combinations of five mutations in CA that conferred complete or near
complete resistance to the disruptive effects of rhTRIM5a on incoming viral cores, by abolishing recognition of the viral
capsid. Importantly, HIV-1 variants encoding these CA substitutions and SIVmac239 Vif replicated efficiently in primary rhesus
macaque lymphocytes. These findings demonstrate that rhTRIM5a is difficult to but not impossible to evade, and doing so
should facilitate the development of primate models of HIV-1 infection.
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Introduction
The narrow species tropism of HIV-1 is, in part, caused by
species-specific variation in restriction factors that inhibit retroviral
infection. This fact has important corollaries, one of which is that
humans are likely protected from infection by many retroviruses.
Conversely, many animal species commonly used in biomedical
research cannot be infected by HIV-1, imposing severe limitations
on the development of non-human primate models of HIV-1
infection and pathogenesis [1]. One antiretroviral protein that
limits HIV-1 tropism is TRIM5a, a restriction factor that was
initially identified in a screen of rhesus macaque (rh, M. mulatta)
genes for inhibitors of HIV-1 infection [2], but in fact can have
broad antiretroviral activity [3–8]. As a member of a large family
of tri-partite motif (TRIM) containing proteins, TRIM5a contains
N-terminal RING, B-box, and coiled-coil domains [9]. TRIM5a,
like other restriction factors such as tetherin and APOBEC3
proteins, inhibits HIV-1 in a species-specific manner [10–17]. In
particular, HIV-1 is vulnerable to restriction by rhTRIM5a but is
resistant to restriction by human TRIM5a due to sequence
differences in their C-terminal PRY/SPRY domains [18–23].
TRIM5a functions by targeting the incoming viral capsid within
minutes of viral entry into the cell cytoplasm [24]. Viral capsids
are likely directly bound by the PRY/SPRY domain during
restriction [25–28] leading to inactivation of the viral core,
followed by dissolution and, in some cases, degradation of viral
core components [27,29,30].
In several instances, restriction factors target generic viral or
cellular features that are required by retroviruses (such as lipid
membranes, dNTP pools, and RNA) in a manner that is not
directly affected by viral RNA or protein sequence. These
nonspecific mechanisms by which restriction factors act makes
viral escape difficult, and the major way that retroviruses evade
such inhibitors is through the acquisition and adaptation of specific
antagonists [31]. For example, the viral proteins Vpu, Nef, Vif and
Vpx are able to rescue HIV-1 or SIV from restriction by human
tetherin, APOBEC3 and SamHD1 proteins by targeting the
restriction factors for removal from their sites of action, or for
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degradation [10,11,13–15,32–38]. In contrast, TRIM5a proteins
are unusual among the known antiretroviral restriction factors,
because they bind to a specific viral protein (CA). While some
TRIM5a proteins, particular those from old world monkeys have
broad antiretroviral activity, and can inhibit retroviruses with
widely divergent CA sequences [3,6–8], the requirement that a
specific protein be recognized affords viruses the opportunity to
evade restriction by evolving a CA protein that cannot be
recognized. Indeed, transplantation of SIVmac239 CA in the
context of a chimeric HIV-1 confers rhTRIM5a resistance
[8,39]. Similarly, sensitivity or resistance of murine leukemia virus
to human TRIM5a can be acquired by mutations in CA
[5,6,40,41]. Amino acids in CA that confer TRIM5a sensitivity
are generally exposed on the surface of the viral core [42,43] and
are therefore accessible for binding to TRIM5a following viral
entry into the cell.
While it should be possible for HIV-1 to evade rhTRIM5a via
changes in CA sequence, it has proven difficult to isolate mutants
of HIV-1 that have this property. A few studies have described
mutations in HIV-1 CA that confer modestly reduced sensitivity to
macaque (M. mulatta or M.fascicularis) TRIM5a proteins [44,45].
Recently one study showed that replacing the entire predicted
surface of HIV-1 CA with SIVmac239 sequences (twenty five amino
acid changes) conferred insensitivity to rhTRIM5a, but at the cost
of an ,15-fold reduction in single-cycle replication fitness [46]. As
yet, no study has reported the identification of mutants that give
full or nearly full resistance to rhTRIM5a while retaining viral
fitness. A possible reason for this is that some monkey TRIM5a
proteins (including rhTRIM5a) are capable of recognizing
retroviral CA proteins (e.g. HIV-1 and MLV) of very different
sequence [3–8]. The molecular basis for this broad antiretroviral
specificity, and consequently the difficulty with which rhTRIM5a
is evaded, may be that rhTRIM5a interacts with multiple
determinants on the 3-dimensional HIV-1 CA protein structure
[46,47]. It is also noteworthy that HIV-1 CA is the most
genetically fragile (intolerant of amino acid substitution) protein
for which robustness/fragility has been quantitatively measured
[48]. Together, these factors may impose a high barrier to the
evolution of fit, rhTRIM5a-resistant HIV-1 strains, an in a
broader sense may be why TRIM5a proteins have been selected
as antiviral proteins during host evolution. If it were straightfor-
ward for retroviruses to acquire resistance to TRIM5a, then little
selective advantage would be conferred on hosts that employ
TRIM5a as an antiretroviral protein.
An appreciation of how and why it is difficult for HIV-1 to
acquire resistance to rhTRIM5a is important for a complete
understanding of factors limiting transmission of primate lentivi-
ruses among divergent primate species. Additionally, overcoming
restriction by rhTRIM5a is required to enable HIV-1 replication
in rhesus macaque cells and, thus, for the generation of an animal
model that is based on HIV-1 infection of rhesus macaques [39].
Successful simian tropic (st) HIV-1 infection of pig-tailed
macaques (M. nemestrina) [49], which express a TRIM5-cyclophilin
fusion (TRIM-Cyp) that is unable to restrict HIV-1 [50–53],
demonstrates that the HIV-1 host-range can include macaques
when APOBEC3- and TRIM5-imposed restrictions are absent.
In the work presented here, we employed various strategies to
identify a number of point mutations in HIV-1 CA that can confer
partial resistance to restriction by rhTRIM5a. By combining
assortments of these mutations, in an assisted evolution approach,
and selecting for viruses that could replicate well in cells expressing
rhTRIM5a, we generated mutant HIV-1 capsids that exhibit
near-complete resistance to rhTRIM5a and retain fitness.
Mutations that conferred resistance to rhTRIM5a were distribut-
ed in several different locations over the exterior surface of the
HIV-1 capsid, suggesting that rhTRIM5a recognizes several
different determinants on HIV-1 CA. The mutations that caused
resistance also abolished the ability of rhTRIM5a to cause
disintegration of HIV-1 core components, as well as the ability of
HIV-1 to saturate rhTRIM5a, suggesting that they exert their
effect by preventing rhTRIM5a binding to CA. Notably, when
incorporated into an stHIV-1 construct that encodes SIVmac239
Vif, rhTRIM5a-resistant CA sequences enabled efficient stHIV-1
replication in primary rhesus macaque lymphocytes.
Results
CA evolution during HIV-1 replication in human T-cell
lines expressing rhTRIM5a
To derive HIV-1 CA proteins that confer resistance to
rhTRIM5a we first employed an adaptation approach in which
HIV-1 was passaged in human cells expressing rhTRIM5a.
Initially, a cloned recombinant virus, termed NHG, that contains
portions of HIV-1NL4-3 and HIV-1HXB2, and encodes GFP in
place of the Nef gene, was grown in MT2 cells to generate a virus
stock with genetic diversity. After fifteen days of replication, cell-
free supernatant was used to infect four different clonal cell lines
stably expressing rhTRIM5a (two derived from MT2 cells and two
derived from MT4 cells) or cells transduced with an empty vector
(Figure 1 A–D). The rhTRIM5a variant used belongs to a class of
rhTRIM5a variants that encode TFP at amino acids 239–241 and
restrict HIV-1 more potently than other variants [54,55]. The first
cycle of HIV-1 replication in these four rhTRIM5a-expressing
lines was restricted by 50- to 100-fold relative to that in the empty
vector control cells, confirming the potent anti-HIV-1 activity of
rhTRIM5a therein (Figure 1 A–D). Infection was monitored by
visual inspection of cytopathic effects and by measuring the
fraction of GFP-positive cells in each culture at 1 to 3 day intervals.
Because MT2 and MT4 cells are exceptionally permissive to HIV-
1 replication (they were selected for this experiment for that
reason), HIV-1 was able to spread through the four cultures and
infect most cells after ,8 days, despite potent inhibition by
rhTRIM5a (Figure 1 A–D). After the majority of cells became
Author Summary
Retroviruses such as HIV-1 often exhibit limited capacity to
infect species other than their natural hosts. This
phenomenon is partly due to the existence of antiviral
proteins that protect against infection by viruses that have
not adapted to a particular species. For example, the
resistance of rhesus macaques, the monkey species most
commonly used in medical research, to HIV-1 infection is
partly attributable to the vulnerability of HIV-1 to TRIM5a.
Rhesus macaque TRIM5a (rhTRIM5a) blocks HIV-1 infection
by recognition of the viral capsid following its entry into
the cell, and it has proven difficult to derive HIV-1 strains
that are resistant to rhTRIM5a. However, by devising an
‘assisted evolution’ approach, we identified particular
combinations of mutations that render HIV-1 resistant to
rhTRIM5a. These mutations enable HIV-1 to evade
rhTRIM5a by abolishing recognition of the capsid. Notably,
introduction of rhTRIM5a-resistant capsids into an HIV-1
that was also engineered to avoid the rhesus macaque
APOBEC3 antiviral proteins, allowed efficient HIV-1 repli-
cation in rhesus macaque lymphocytes. These discoveries
have the potential to advance the development of rhesus
macaque models of HIV-1 infection.
Rhesus Macaque TRIM5a-Resistant HIV-1
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GFP-positive and cytopathic effects had become abundant in the
cultures, cell free supernatants were used to inoculate fresh
rhTRIM5a-expressing cells, and this process was repeated for 10
passages in each of the four cell lines. The time taken for the
majority of the cells to become GFP-positive during each passage
appeared to decrease as the number of passages increased (Figure 1
A–D), implying adaptation of the virus to the rhTRIM5a
expressing cells. At each passage, we measured the infectious
HIV-1 titer in the four culture supernatants on both rhTRIM5a
expressing and empty vector expressing cell lines. These analyses
indicated that there was a progressive decrease in the sensitivity of
the virus population to rhTRIM5a as the number of passages on
rhTRIM5a expressing cells increased (Figure 1E–H). However,
even the passaged virus stock retained at least some degree of
sensitivity to rhTRIM5a, and each of the four adapted viruses was
restricted by ,5- to 10-fold after 6 to 8 passages. Sensitivity to
rhTRIM5a did not appear to decrease with further passage
(Figure 1E–H).
PCR amplification and bulk sequencing of viral DNA present in
the four rhTRIM5a expressing cell cultures after various numbers
of passages revealed that four CA mutations (V86E, I91N, I91T,
and G116E) were present at a sufficiently high frequency to be
detected in bulk sequences (Table 1). These mutations occurred at
three different codons, all of which specified amino acids that are
exposed on the presumptive outer face of the viral core (Figure 2A).
Specifically, amino acids V86 and I91 are both within the
Figure 1. HIV-1 adaptation in human cell lines expressing rhTRIM5a. (A–D) MT2 and MT4 cells expressing either rhTRIM5a (filled symbols) or
an empty vector (open symbols) were infected with HIV-1NL4-3/HIV-1HXB2/GFP (NHG). Aliquots of cells from each culture were withdrawn and fixed for
FACS analysis at the indicated times and the percentage of cells that were positive for GFP is plotted versus days after the infection of the first culture.
Discontinuities indicate points at which cell-free supernatant was harvested and used to initiate the next passage in TRIM5a-expressing cell lines.
NHG was passaged in four different cell lines expressing rhTRIM5a: MT2-rhTRIM5a#8 (A), MT2-rhTRIM5a#15 (B), MT4-rhTRIM5a#29 (C), and MT4-
rhTRIM5a#32 (D). (E–H) Viral sensitivity to TRIM5a (Fold restriction) was calculated as the ratio of infectious titers present in culture supernatants at
the end of each passage shown on the left, measured on MT2-vector and MT2-rhTRIM5a#8 cells.
doi:10.1371/journal.ppat.1003667.g001
Rhesus Macaque TRIM5a-Resistant HIV-1
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cyclophilin-binding loop and G116 is on an outer turn of helix six
(Figure 2A). Strikingly, each of the four mutations occurred in
each of the four parallel virus cultures. In some cases, the mutant
codons were present as mixtures with the WT codons, while in
others WT codons became undetectable. In three virus cultures,
all four amino acid changes were present in viral populations
sampled after ten passages, at which point the WT I91 codon was
no longer detected. Conversely, in one viral lineage, mutations at
I91 were detected at passage 4, but then disappeared from the
culture, and were undetectable after the tenth passage, at which
point only V86E and G116E mutations were present as mixtures
with the WT codon at both positions. Notably, amino acid
substitutions V86M (V86E is described here) and G116E have
previously been shown to decrease sensitivity to rhTRIM5a and
crab-eating macaque TRIM5a, respectively [44,45].
To determine whether and how mutations that arose in CA
during passage decreased sensitivity to rhTRIM5a, PCR products
amplified from viral cultures were cloned and inserted into the
parental pNHG proviral plasmid. The resulting clones included
four single CA mutants; V86E, I91N, I91T and G116E, as well as
double-mutants I91N/G116E and I91T/G116E. Certain combi-
nations of mutations were not recovered as individual species from
the four viral cultures, and so site-directed mutagenesis was used to
construct all other possible double and triple mutant combinations
of V86E, I91T, I91N and G116E (see below). To test the resulting
viruses for sensitivity to rhTRIM5a, single-cycle infection assays
were employed, using the MT2 cell lines expressing either
rhTRIM5a or an empty vector as targets (Figure 2B).
All four of the single amino acid mutants (V86E, I91N, I91T
and G116E) exhibited decreased rhTRIM5a sensitivity. In
particular, substitutions V86E and I91T each reduced rhTRIM5a
sensitivity from ,60-fold inhibition to ,15-fold (Figure 2B). The
I91N/G116E and I91T/G116E double mutants exhibited even
lower rhTRIM5a sensitivity and were inhibited by less than 10-
fold. Notably, the aforementioned mutants all occurred in
individual species that were present in the viral culture experiment
and exhibited little or no decrease in infectivity on the vector
control cell line, suggesting that these individual and combined
mutations did not incur major fitness costs. The data obtained
with these reconstructed viral clones correlated quite well with the
results obtained with each uncloned viral stock harvested after 10
passages in MT2-rhTRIM5a (Figure ’1E–H). Specifically, virus
populations harvested from MT4-rhTRIM5a#29 carried V86E
and G116E, but not I91T or I91N, and this stock was restricted by
16-fold by rhTRIM5a. Conversely the other three uncloned,
adapted viruses all carried I91T, I91N, and G116E and were
restricted by only 5–10 fold.
We next reconstructed the viral mutants that contained
combinations of the aforementioned substitutions that were not
detected as individual species in the passage experiment, namely
the V86E/I91N, V86E/I91T and V86E/G116E, double mutants
and the V86E/I91N/G116E and V86E/I91T/G116E triple
mutants. Strikingly, some of these mutants appeared completely,
or nearly completely resistant to rhTRIM5a restriction in MT2
cells (Figure 2B). However, those mutants also exhibited severely
reduced titers on the control vector expressing MT2 cell line,
indicating that large fitness costs were imposed by combinations of
mutations that gave rhTRIM5a resistance. The V86E/I91N and
V86E/I91T double mutants also had apparent fitness defects that
accompanied improvements in resistance to rhTRIM5a. These
fitness costs were also observed in the context of spreading
replication assays (Figure S1). Specifically, while the partially
rhTRIM5a-resistant I91N/G116E and I91T/G116E double
mutants were able to replicate as rapidly as WT on control vector
expressing MT2 cells, the other combinations of mutations,
particularly the V86E/I91N/G116E and V86E/I91T/G116E
triple mutants, resulted in attenuated replication (Figure S1).
Surprisingly, replication of these triple mutants was inhibited by
rhTRIM5a during spreading replication assays (Figure S1), even
though they appeared nearly completely resistant in single-cycle
infection assays (Figure 2), suggesting the possibility that poor
fitness might amplify the effect of residual restriction by
rhTRIM5a during spreading replication assays. Notably, the
attenuated double and triple mutants exhibited low titer in
hamster pgsA cells, but were not sensitive to restriction by human
TRIM5a expressed therein (Figure S2). This finding indicates that
the apparent fitness defects observed in human cell lines were not
due to acquisition of sensitivity to endogenous human TRIM5a,
but instead were TRIM5a-independent deficits that coincided
with decreases in sensitivity to rhTRIM5a. It therefore appeared
that, in spite of the potential for HIV-1 CA to acquire near
complete rhTRIM5a resistance via two or three amino acid
substitutions, deleterious effects on fitness prevented some
combinations of mutations from emerging as individual species
during adaptation on rhTRIM5a expressing cell lines.
All four of the capsid amino acid changes that arose during
evolution in the rhTRIM5a cell lines were the result of single
nucleotide substitutions. We considered the possibility that other
amino acid substitutions at the same positions in CA would have
conferred a greater degree of rhTRIM5a resistance, but simply
did not arise because of their requirement for two or three
nucleotide changes in a single codon. To address this possibility,
we conducted a vertical mutagenesis experiment, in which we
made every possible amino acid substitution at positions 86, 91,
and 116 in CA. Thereafter, we screened each of the 57 single
amino acid substitutions for rhTRIM5a sensitivity (Figure S3A, B,
C). A variety of mutations at positions 86, 91, and 116 decreased
TRIM5a sensitivity. For example, at position 91 there were six
different amino acid substitutions (I91A, I91P, I91Q, I91Y, I91D,
and I91E) that were phenotypically approximately equivalent to
Table 1. Amino acid changes arising during HIV-1 passage in rhTRIM5a expressing cell lines.
Passage Number Cell Line
MT2#8 MT2#15 MT4#29 MT4#32
P5 (MT2) or P4 (MT4) V86E I91N,T G116E V86E I91N G116E V86E I91N,T G116E V86E I91N,T G116E
P7 (MT2) or P6 (MT4) V86E I91N,T G116E I91N G116E V86E I91N,T G116E
P10 V86E I91N,T G116E V86E I91N,T G116E V86E G116E V86E I91N,T G116E
Amino acids symbols are bold where the WT codon was not detected in the sequence chromatogram. In other cases, the mutant was present as a mixture with the WT
codon.
doi:10.1371/journal.ppat.1003667.t001
Rhesus Macaque TRIM5a-Resistant HIV-1
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I91N and I91T. There were also several amino acid changes at
position 91 that conferred a greater degree of TRIM5a resistance
than I91N or I91T, but all of them caused decreases in viral titer.
For example, the I91G substitution gave near complete
rhTRIM5a resistance, but this mutation caused a 70-fold loss in
viral titer on empty vector expressing cells (Figure S3B). Several
different substitutions at positions 86 and 116 also conferred
partial resistance to rhTRIM5a, but often these effects were
accompanied by reduced viral titer. At position 86, most
substitutions caused reduced rhTRIM5a sensitivity and a gluta-
mine substitution caused the largest increase in viral titer on MT2-
rhTRIM5a (Figure S3A). However, when V86Q was combined
with substitutions at I91 and/or G116 it did not exhibit higher
viral titers on MT2- rhTRIM5a cells than the double mutants that
emerged during the viral evolution experiments described in
Figures 1 and 2 (unpublished observations). At position 116, none
of the mutants exhibited higher titer on MT2-rhTRIM5a than did
G116E (Figure S3C). Thus it appeared that the adaptation
experiment selected near-optimal amino acids at positions 86, 91
and 116, but was not capable of selecting CA mutants with
combinations of mutations that conferred the desired property.
Because our selection experiments were done in human cells, it
was possible that endogenous human TRIM5a could have limited
the spectrum of rhTRIM5a-resistance mutations that arose at
these positions. Indeed, mutations at positions 86, 91, and 116
have been associated with sensitivity to human TRIM5a in the
context of cytotoxic T lymphocyte escape [56]. Therefore, we
screened the vertical mutant collection for sensitivity to human
TRIM5a (Figure S4 A, B, C). Although some sensitivity to human
TRIM5a was observed in some mutants, these effects were minor:
while N-MLV was restricted by 160-fold by huTRIM5a, the
degree to which some HIV-1 CA mutants were restricted was
usually not more than 2- to 3-fold. One mutant, V86W, was
restricted 6-fold by huTRIM5a. Therefore, it seems unlikely that
endogenous TRIM5a would have profoundly limited evolution at
these three positions during the adaptation experiment.
A screen of a randomly mutated CA library for
substitutions conferring rhTRIM5a resistance
In a second independent strategy to identify mutations in HIV-1
CA that might confer rhTRIM5a resistance, we screened 91
infectious mutants from a library of NHG clones encoding PCR-
mutagenized CA proteins (see Materials and Methods). MT2 cells
expressing either the empty vector or rhTRIM5a were infected in
a single cycle assay with a single dose of each clonal mutant virus
and the ‘fold restriction’ by rhTRIM5a was calculated for those
CA mutants that yielded measurable infectivity (.0.1% infected
cells) on MT2-rhTRIM5a cells (Figure 3A). The parental virus,
NHG was restricted by over 100-fold, as expected, while 22 CA
mutant clones were restricted by less than 50-fold. The infectious
titer of these 22 mutants was measured on vector expressing and
rhTRIM5a expressing cells to confirm their decreased rhTRIM5a
sensitivity (Figure 3B). Although there were a variety of mutations
that decreased apparent rhTRIM5a sensitivity, many also
decreased viral titer on vector-expressing cells. For example,
N57S was restricted by only 8-fold by rhTRIM5a, but its
infectious titer on vector control cells was reduced 30-fold as
compared to the parental NHG virus. Therefore, we selected only
mutants that conferred increased titer on rhTRIM5a-expressing
cells as candidates that had the potential to contribute to a CA that
was both fit and resistant to rhTRIM5a. The infectivity of these
mutants on control vector expressing cells was equivalent to or
only marginally decreased compared to the parental virus.
Interestingly, two such mutations, V86E and I91T, had
also emerged in the viral evolution experiments presented in
Figures 1 and 2. Additionally, we selected M10L, M10V, V83M,
H87Q, R100S, and A105T as candidate mutations for further
analysis because they also caused an increase in infectivity on
MT2-rhTRIM5a cells. Of note, each of these amino acid
substitutions occurred at positions that are predicted to be exposed
to the cytoplasm after viral entry (Figure 3C).
Fit, rhTRIM5a-resistant viruses, evolved from an assorted
pool of CA mutants
While the above experiments demonstrated that a variety of
mutations could confer partial resistance to rhTRIM5a, none of
the aforementioned single amino acid CA mutants generated fully
resistant viruses that did not incur a large fitness cost. However,
the I91N/G116E and I91T/G116E double mutants demonstrated
the potential for the additive effect of multiple mutations in the
acquisition of TRIM5a resistance, without fitness penalties
(Figure 2). Conversely, for other double mutants, particularly the
combination of V86E and G116E, mutations that conferred
partial rhTRIM5a resistance and had little fitness cost on their
own, combined to generate rhTRIM5a resistant viruses at the
expense of large fitness costs (Figure 2). Thus, it was possible that
combinations of mutations that we had identified might generate
fully rhTRIM5a-resistant viruses, but it was unpredictable as to
whether and which combinations of mutations would allow the
maintenance of high viral fitness.
Therefore, in an attempt to derive combination mutant CA
proteins that were both fully fit and rhTRIM5a resistant, we
adopted an ‘assisted evolution’ approach and generated a viral
population that contained all possible combinations of the
aforementioned non-deleterious mutations that conferred partial
TRIM5a resistance (Figure 4A). Overlapping oligonucleotides that
contained degenerate nucleotides encoding mixtures of WT and
mutant amino acids were used to assemble a synthetic CA library
pool containing random assortments of the mutations M10L/V,
L83M, V86E, H87Q, I91N/T, R100S, A105T, and G116E. The
synthetic CA assortment was used to generate a proviral plasmid
library whose theoretical complexity was 576. Proviral plasmid
DNA was isolated from 2.56103 pooled bacterial colonies and
transfected as a mixture, yielding a viral population that should
contain every possible combination of the above mutations.
This viral population was evolved in MT2-rhTRIM5a through
a series of 15 passages (Figure 4B). Additionally, the final four
passages were also carried out in CEM-rhTRIM5a cells. The
Figure 2. HIV-1 CA mutations selected during passage in rhTRIM5a-expressing cells decrease sensitivity to rhTRIM5a. (A) Positions of
amino acid residues at which mutations arose during replication in cells expressing rhTRIM5a are indicated on the HIV-1NL4-3 capsid hexameric
structure [43]. V86E and I91N/T are in the cyclophilin-binding loop and G116E is in helix six. The capsid hexamer shown on the left represents the
exterior of the viral core, viewed from the cytoplasm of an infected cell. The hexamer on the right is oriented with the cytoplasmic face toward the
top of the picture and the residues that face toward the interior of the core on the bottom. Images were generated using MacPyMOL. (B) NHG (WT) or
NHG derivatives carrying the indicated mutations were titrated on MT2-vector (open symbols) or MT2-rhTRIM5a#8 (filled symbols) cells. Single-cycle
infectivity was determined by FACS analysis. Mutant CA sequences that were found in the passaged viral population are marked with a green asterisk
while mutants that were not found in the passaged viral population but were constructed using site-directed mutagenesis are marked with a red
asterisk.
doi:10.1371/journal.ppat.1003667.g002
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rationale for this was that CEM cells are less permissive than MT2,
and we reasoned that this might impose a more stringent
requirement for rhTRIM5a resistance and high replicative fitness
on the viral population. Unfortunately, beginning at about passage
10, the maximum number of GFP-positive cells began to decrease
with each subsequent passage (Figure 4B), presumably as a result
of inactivating mutations in the GFP reporter gene in NHG.
Nonetheless, visual inspection of cytopathic effects suggested that
virus replication accelerated during the serial passage experiment.
We conducted PCR amplification and bulk sequencing of viral
DNA from infected cells at passage 4, 9, 11 and 15 (Table 2). This
analysis revealed that some mutations were purged from the viral
population at varying rates while others apparently became fixed.
Additionally, new mutations arose during passage. Specifically,
V86E, R100S, and A105T were rapidly purged (by passage 4)
while L83M and H87Q were detected at passage 4, 9,and 11, but
lost by passage 15. Conversely, mutations M10L, I91N, and
G116E became dominant in the viral population, with I91N and
G116E rising to dominance rapidly and M10L becoming
dominant in MT2 cells (but not CEM cells) between passages 11
and 15. Two additional mutations, namely A92E and M96I, that
were not deliberately included in the starting assortment, arose
spontaneously and became dominant in the viral population in
MT2-rhTRIM5a cells. Curiously, these cyclophilin-binding loop
mutations arose at about the same time as two other cyclophilin-
binding loop mutations (L83M and H87Q) were lost from the
population, suggesting the possibility that these mutations were not
compatible with each other. It is also possible that A92E and M96I
have the same biological effect as L83M or H87Q but at a lower
fitness cost. The apparent lack of heterogeneity at the aforemen-
tioned positions in the bulk PCR product suggested that a single
CA species containing five mutations (M10L, I91N, A92E, M96I
Figure 3. Screen of random HIV-1 CA mutants for rhTRIM5a resistance. (A) NHG clones containing CA substitutions generated by random
mutagenesis were used to challenge MT2 cells expressing an empty vector or rhTRIM5a using a single dose of each virus. Fold-restriction by
rhTRIM5a (the ratio of the numbers of infected cells in each cell line) is plotted. Only data from viruses that gave measurable infectivity (.0.1%
infected cells) in MT2-rhTRIM5a cells are plotted. The WT NHG is plotted as a red symbol and viruses restricted by less than 50-fold are represented by
open symbols. (B) NHG mutants carrying CA mutations that decreased TRIM5a sensitivity were retested and infectious titers in MT2-vector (open
symbols) and MT2-rhTRIM5a#8 (filled symbols, referencing the left Y-axis) cells, as well as the ratio of these titers (fold restriction red triangles,
referencing the right Y-axis) are plotted. (C) Two views of the NL4-3 capsid hexamer [43] are shown, as in Figure 2B. The sites of amino acid
substitutions found in (B) to increase infectious titer on MT2-rhTRIM5a cells (M10L, V83M, V86E, H87Q, I91T, R100S and A105T) regardless of effects on
titer in vector control cells are indicated.
doi:10.1371/journal.ppat.1003667.g003
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and G116E) had come to dominate the population in MT2-
rhTRIM5a cells (Table 2). In CEM-rhTRIM5a cells, the results
were slightly different in that a single species did not dominate the
population at passage 15. Rather M10L and M96I were present as
mixtures with the WT codons, and a third spontaneous mutation,
L52I, was identified, again as a mixture with the WT codon.
Sequences encoding CA were cloned from the viral DNA
present in both MT2-TRIM5a and CEM-TRIM5a cell lines at
Figure 4. An assisted evolution strategy to derive fit, rhTRIM5a-resistant HIV-1 strains. (A) Schematic representation of the experimental
design used to select fit, rhTRIM5a resistant viruses. CA mutations shown to decrease TRIM5a-mediated restriction, without major fitness penalties
were incorporated into a synthetic CA amplicon to generate a virus population containing random assortments of the mutations. (B) Serial passages
of the virus population described in (A) in MT2-rhTRIM5a cells (filled symbols). Infection was monitored by measuring the proportion of cells
expressing GFP over time, as described in the legend to Figure 1. In parallel, the last four of fifteen serial passages were also carried out in CEM-
rhTRIM5a cells (open symbols).
doi:10.1371/journal.ppat.1003667.g004
Table 2. Amino acid changes present during passage of HIV-1 encoding an assortment of CA mutations in a rhTRIM5a expressing
cell line.
Passage Number Amino Acid residue:
M10 L83 V86 H87 I91 R100 A105 G116 A92 M96 L52
P4 L M Q N, T E
P9 L M Q N E E
P11 L M Q N E E I
P15 (MT2) L N E E I
P15 (CEM) L N E E I I
Amino acids symbols are bold where the WT codon was not detected in the sequence chromatogram. In other cases, the indicated mutation was present as a mixture
with the WT codon.
Changes that arose during replication and were not present in the starting assortment (A92E, M96I, L52I) are shown on the right.
doi:10.1371/journal.ppat.1003667.t002
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passage 15. One clone, containing the substitutions M10L/I91N/
A92E/M96I/G116E (LNEIE), corresponded to the dominant
species in MT2-rhTRIM5a cells and the other, L52I/I91N/
A92E/M96I/G116E (INEIE), corresponded to a species that was
co-dominant with LNEIE in CEM-rhTRIM5a cells. With the
exception of L52I, all of the aforementioned mutations that
became fixed, or arose during the passage experiment, were at
residues that are predicted to be exposed on the surface of the
HIV-1 capsid (Figure 5A).
We next compared the properties of the species that arose via
assisted evolution from the assorted CA mutant pool (LNEIE and
INEIE, Figure 5A), with the best performing virus species (in terms
of fitness and rhTRIM5a resistance) that arose spontaneously
during the initial passage in rhTRIM5a expressing cell lines,
namely I91N/G116E (NE) (Figure 5B). Additionally, because
L83M was among the best performing mutations in the random
mutagenesis screen (Figure 3B) and may not have had the
opportunity to coexist with the late appearing and proximal A92E
and M96I mutations, we also used site-directed mutagenesis to
introduce L83M into LNEIE to generate a virus carrying six
mutations M10L/L83M/I91N/A92E/M96I/G116E (LMNEIE,
Figure 5B).
While the I91N/G116E (NE) double-mutant was restricted in
MT2-rhTRIM5a by ,5-fold, LNEIE, INEIE and LMNEIE were
completely or nearly completely resistant to inhibition by
rhTRIM5a in single cycle infection assays, similar to a virus
expressing the SIVmac239 CA (Figure 5C). Moreover in spreading
replication assays, LNEIE, LMNEIE, and INEIE replicated with
equivalent kinetics in rhTRIM5a-expressing MT2 cells and empty
vector expressing MT2 cells (Figure S5). Moreover, the titers and
replication kinetics of these viruses on non-restricting MT2 cells
were indistinguishable from that of NHG (Figures 5C and S5).
Thus, an assisted evolution approach, in which mutations that
individually had modest effects on rhTRIM5a were randomly
combined and subjected to selection in cell culture, enabled the
acquisition of near complete rhTRIM5a resistance, with apparent
retention of viral fitness in this cell line.
In some human cells lines, the A92E mutation, which was
present in the LNEIE, LMNEIE, and INEIE mutants, has been
shown to cause HIV-1 infection to become inhibited by
cyclophilin A (CypA). Consequently, infection by A92E CA
mutant viruses is increased in the presence of cyclosporin A (CsA),
a drug that disrupts the CA-CypA interaction [57–59]. To test
whether the CsA-dependence observed in A92E mutants is also
present in the context of LNEIE, LMNEIE, or INEIE, VSV-G
pseudotyped WT and mutant viruses were titrated on HeLa cells
in the presence or absence of CsA (Figure S6). As has previously
been shown to be the case in HeLa cells [57], the presence of CsA
increased infection by the A92E mutant by .10-fold. In contrast,
the enhancing effect of CsA on infection was minor in the case of
LNEIE (2-fold) and absent in the case of NHG, LMNEIE, and
INEIE.
Lack of rhTRIM5a induced core disruption in rhTRIM5a-
resistant viruses
To further demonstrate resistance of the aforementioned CA
mutant viruses to rhTRIM5a, we tested whether viruses carrying
the CA mutations were able to avoid the disruptive effects of
rhTRIM5a on incoming viral cores [27,29,30], and thereby
complete reverse transcription. To accomplish this, we employed
our recently described assay in which the integrity of a subviral
complex containing CA, integrase (IN) and viral nucleic acids is
monitored in infected cells shortly after infection [30]. Specifically,
VSV-G pseudotyped viruses encoding either WT or mutant CA
proteins were generated, and equivalent amounts (Figure 6A) were
applied to pgsA-745 or pgsA-rhTRIM5a cells, in a synchronized
infection protocol. Two hours later, cytoplasmic extracts were
fractionated and the presence of CA and IN protein, as well as
viral cDNA was measured in each fraction. As expected, in the
case of WT HIV-1, a dense complex containing CA and IN as well
as viral DNA was readily detected in infected pgsA cells
(Figure 6B). This complex appeared largely absent in identically
infected pgsA-rhTRIM5a cells, consistent with the notion that
rhTRIM5a disrupts incoming HIV-1 cores. In contrast, the dense
complex containing CA and IN, as well as viral DNA, was not
disrupted by rhTRIM5a during infection with viruses encoding
the LNEIE, LMNEIE, INEIE, or NE CA mutants (Figure 6C–F)
and only minor differences in the levels of CA, IN, and viral DNA
in the dense complex were observed. These data suggest that the
subviral complexes generated by LNEIE, LMNEIE, INEIE, and
NE CA mutant viruses are preserved in the presence of
rhTRIM5a and thus that the cores of these viruses are largely
resistant to the biochemical effects of rhTRIM5a. Although the
NE CA mutant retained residual sensitivity to rhTRIM5a in
MT2-rhTRIM5a cells (Figure 5C), all four CA mutants (NE,
LNEIE, LMNEIE, and INEIE) were able to infect pgsA-
rhTRIM5a cells at similar levels (Figure S7). The minor
differences among the four mutants in pgsA-rhTRIM5a cells
were, apparently, insufficient to be evident in the biochemical
assay of rhTRIM5a restriction (Figure 6C–F).
CA mutations conferring rhTRIM5a resistance prevent
recognition by rhTRIM5a
In principle, the above HIV-1 mutants may have acquired
resistance to rhTRIM5a by avoiding recognition by rhTRIM5a
or, less likely, by acquiring the ability to infect cells despite
recognition by rhTRIM5a. To distinguish between these possibil-
ities we performed an ‘abrogation of restriction’ assay. TRIM5a
proteins can, in general, be saturated by high amounts of incoming
capsids, thereby enabling infection by viruses that would otherwise
be restricted [7,60]. The ability of a given viral capsid to abrogate
TRIM5a mediated restriction is thus taken as a surrogate of its
ability to be recognized by and bind to that TRIM5a protein.
Therefore, we determined whether HIV-1 particles carrying the
rhTRIM5a-resistant CA proteins were capable of abrogating
rhTRIM5a activity in the rhesus macaque cell line, FRhK-4.
VSV-G enveloped HIV-1 particles carrying a minimal HIV-1
genome (lacking GFP) and GagPol proteins that included either
WT or the aforementioned rhTRIM5a-resistant CA sequences
were first normalized according to their infectious titer on TZM
indicator cells. FRhK-4 cells were challenged with increasing
amounts of these viral particles along with a fixed amount of a
virus containing WT HIV-1 GagPol protein and a genome that
encoded a GFP reporter. As expected, infecting FRhK-4 cells in
the presence of abrogating HIV-1 virions encoding a WT CA
protein dramatically increased the titer of a WT GFP reporter
virus (Figure 7A). Notably however, HIV-1 virions encoding
rhTRIM5a-resistant CA mutants (NE, LNEIE, INEIE and
LMNEIE) failed to abrogate restriction (Figure 7A). the residual
sensitivity to rhTRIM5a that was observed for the NE CA mutant
in in MT2-rhTRIM5a cells, was barely evident in FRhK4 cells,
and all four CA mutants (NE, LNEIE, INEIE and LMNEIE)
exhibited only minor variation in infectivity therein (Figure S8).
The lack of abrogation activity displayed by the CA mutants
strongly suggests that the mechanism by which the CA mutations
conferred rhTRIM5a resistance was through loss of specific
recognition by rhTRIM5a. Consistent with this conclusion, each
of the rhTRIM5a-resistant viruses was inhibited by owl monkey
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Figure 5. Selection of fit, rhTRIM5a-resistant viral clones from a synthetic CA library containing assortments of mutations
conferring partial rhTRIM5a resistance. (A) Two views of the HIV-1 capsid hexamer [43] are shown, as in Figure 2B. The sites of amino acid
substitutions in the species (LNEIE) that became dominant in MT2-rhTRIM5a cells, or codominant in CEM-rhTRIM5a cells (LNEIE and INEIE) following
the assisted evolution experiment described in Figure 5 are shown. (B) For comparison, the sites of amino acid substitutions in the best performing
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Figure 6. RhTRIM5a-resistant mutants are immune to viral core disruption by rhTRIM5a. (A) Virions harvested from cells transfected with
plasmids expressing HIV-1NL4-3 GagPol (WT or CA mutants), VSV-G, and an HIV-1 vector carrying a GFP reporter were pelleted through 20% sucrose
and CA protein was detected by western blotting. (B–F) PgsA (none) and pgsA-rhTRIM5a (rhT5a) cells were infected with VSV-G pseudotyped HIV-
1NL4-3 (WT or CA mutants), carrying a GFP reporter. Infected cells were harvested at T = 2 hr. after infection and post-nuclear supernatants were
fractionated on 10–50% (w/v) sucrose gradients as described in Materials and Methods. Ten fractions were collected from the gradients. Q-PCR
analysis of reverse transcription products and western blot analysis of CA and integrase (IN) in each fraction is represented for HIV-1NL4-3 with WT (B),
LNEIE (C), LMNEIE (D), INEIE (E) and NE (F) CA sequences.
doi:10.1371/journal.ppat.1003667.g006
mutant (NE) derived in the standard selection experiment described in Figure 1 as well as an LNEIE derivative containing an additional substitution
(LMNEIE) are also shown. (C) NHG, an NHG derivative encoding an SIVmac239 capsid, or NHG derivatives carrying the indicated combination of amino
acid substitutions were used to infect MT2-rhTRIM5a#8 cells (filled symbols) or MT2 cells transduced with empty vector (open symbols).
doi:10.1371/journal.ppat.1003667.g005
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TRIMCyp (Figure 7B), indicating that they were intrinsically
sensitive to a TRIM5 protein that is able to bind to these capsids.
HIV-1 strains encoding rhTRIM5a-resistant CA proteins
and SIVmac Vif replicate in rhesus macaque lymphocytes
Along with APOBEC3 proteins, TRIM5a imposes a major
block to HIV-1 replication in rhesus macaque cells [39]. To
determine whether HIV-1 mutations that conferred resistance to
rhTRIM5a expressed in human cell lines enabled replication in
primary rhesus macaque cells, the TRIM5a-resistant CA
sequences NE, LNEIE, INEIE and LMNEIE were inserted into
a chimeric HIV-1 containing SIVmac239 Vif, named stHIV-1 [49].
Virus stocks bearing either WT, NE, LNEIE, INEIE, LMNEIE or
SIVmac239 (stHIV-SCA) [39] CA sequences were normalized for
reverse transcriptase content and used to challenge peripheral
blood mononuclear cells (PBMC) from two rhesus macaque
donors (Figure 8). As expected, stHIV-1 carrying the WT HIV-1
CA sequence failed to replicate, while stHIV-SCA carrying the
SIVmac239 CA initiated a spreading infection. Notably, all four
rhTRIM5a-resistant CA sequences enabled efficient stHIV-1
replication in rhesus macaque PBMC. In one donor, the
rhTRIMa-resistant CA mutants replicated similarly to stHIV-
SCA while in a second, apparently less permissive donor, all of the
CA-mutant HIV-1 strains outperformed stHIV-SCA (Figure 8).
The LNEIE mutant appeared to perform marginally better than
the other CA mutants, and better than stHIV-SCA in PBMC from
both donors. Genotyping revealed that both donors were
heterozygous for rhTRIM5a alleles. The first donor carried alleles
4 and 5, while the second carried alleles 3 and 4 as (following the
nomenclature described by Newman et al and Wilson et al [54,55]).
Alleles 4 and 5 belong to a class that encodes a glutamine at
residue 339 and allele 3 belongs to a class that encodes TFP at the
same position. These two classes of rhTRIMa variants have been
shown to differ in their restriction specificity and potency [54,55].
Importantly, the ability of the HIV-1 mutants described here to
replicate in PBMC from both animals suggests that they have
acquired resistance to restriction by both classes of rhTRIM5a
alleles.
Discussion
In this study, we identified a number of mutations in HIV-1 CA
that individually could reduce the sensitivity of the incoming
capsid to restriction by rhTRIM5a. When present in the right
combination, collections of these mutations could confer near
complete resistance to rhTRIM5a, sometimes without a fitness
cost. Indeed, mutations in capsid were necessary and sufficient for
HIV-1 to evade restriction by rhTRIM5a, consistent with the
notion that the antiviral activity of TRIM5 depends on specific
capsid recognition [5,8,39,40,47]. The rhTRIM5a resistant CA
sequences abolished the ability of rhTRIM5a to disrupt incoming
HIV-1 cores, enabling reverse transcription and the formation of a
complex containing CA, IN and viral DNA, which would
normally be blocked by rhTRIM5a [30]. Ultimately, these
mutations enabled uninhibited infection of human cell lines stably
expressing rhTRIM5a, which ordinarily exhibit .50-fold reduced
susceptibility to WT HIV-1 infection.
With one exception, the amino acid substitutions that were
found in the rhTRIM5a-resistant CA sequences encoded amino
acids that are exposed on the presumptive exterior surface of the
capsid lattice. However, L52I, (which occurred in only one of two
cell lines in which the assorted CA mutant pool was evolved) is
buried in the interior of the CA protein structure [43]. It is possible
that L52I contributes to resistance by shifting the conformation of
Figure 7. RhTRIM5a-resistant HIV-1 capsids are not recognized
by rhTRIM5a. (A) The indicated CA sequences were tested for their
ability to generate viral capsids that could saturate rhTRIM5a in a rhesus
macaque cell line. FRhK-4 cells were infected with VSV-G pseudotyped
virions containing HIV-1NL4-3 GagPol proteins encoding either wildtype
CA, SIVmac239 CA, or the indicated mutant CA. An HIV-1 based vector
that encoded Tat was packaged into these virions and ‘abrogating virus
dose’ is given in TZM infectious units (I.U.). Cells were tested for
rhTRIM5a abrogation by simultaneous infection with a fixed amount of
a VSV-G pseudotyped virions carrying a WT HIV-1NL4-3 GagPol and a
GFP-reporter gene. (B) VSV-G pseudotyped virions carrying the
indicated WT or mutant CA-encoding HIV-1NL4-3 GagPol and a GFP-
reporter gene were used to infect pgsA-745 cells or pgsA-745 cells
stably expressing owl monkey TRIM-Cyp. Cells (16104) were infected
with 2 mL of supernatant from transfected 293T cells.
doi:10.1371/journal.ppat.1003667.g007
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the capsid surface. Alternatively, it may marginally stabilize or
destabilize the viral core, thereby affecting rhTRIM5a action. It is
also possible that L52I, or indeed other mutations described
herein, arose as a compensatory mutation to maintain high viral
fitness while not directly contributing to rhTRIM5a resistance.
The contribution of the L52I mutation in the interior of the CA
structure notwithstanding, the primary mechanism by which the
HIV-1 CA mutants acquired resistance to rhTRIM5a appeared to
be through loss of rhTRIM5a recognition, rather than resistance
to the effects of TRIM5a after recognition of the incoming capsid.
This conclusion is based on the findings that (i) rhTRIM5a-
resistant mutant capsids were unable to saturate rhTRIM5a and
thereby facilitate WT HIV-1 infectivity in rhesus macaque cells,
suggesting that they were not recognized by rhTRIM5a and (ii)
the rhTRIM5a-resistant capsids retained full sensitivity to another
TRIM5 protein (omkTRIMCyp) with a different CA binding
specificity. Neither of these results would be expected if resistance
were acquired via a mechanism in which the viral capsid retained
rhTRIM5a binding, but acquired the ability to resist its antiviral
effects.
Our initial failure to derive HIV-1 variants with complete
resistance to rhTRIM5a through replication in cell lines express-
ing this inhibitor, or through random mutagenesis, underscores
the difficulty in deriving HIV-1 strains with this property. Indeed,
our eventual success required the combined application of the two
different approaches, and then further evolution during selection
from an assortment of mutations identified by each strategy. A
comparison of the results obtained from the initial adaptation
(Figure 2) and random mutagenesis (Figure 3) approaches suggests
that each had distinct advantages and disadvantages. Despite the
fact that four parallel cultures were initiated, the adaptation
approach clearly did not produce a wide variety of solutions, and
the same four mutations (V86E, I91N, I91T, and G116E) arose in
four independent cultures. No combination of these four
mutations gave fully fit rhTRIM5a-resistant CA sequences. It is
possible that this result is defined by a potentially limited
complexity of the viral population to which selection pressure
was applied, and that rather than selection of several independent
solutions, a small number of initially dominant genotypes
persisted. However, another explanation might be that mutations
that reduce HIV-1 sensitivity to rhTRIM5a without a fitness cost
are few in number. Consistent with this latter interpretation is the
fact that 2 of the 3 positions that we found to be mutated in
rhTRIM5a-selected viruses have also been identified in similar,
but completely independent, selection experiments in other
laboratories, in different cell lines [44,45]. Those mutations that
confer rhTRIM5a resistance but are marginally deleterious to
virus replication might not be selected during the adaptation
approach, even though they could contribute rhTRIM5a evasion
if their accompanying fitness costs were alleviated by compensat-
ing mutations. Screening a random library of virus clones might be
a better way to identify such mutants. Indeed, the random
mutagenesis screen identified a larger number of mutants that
conferred reduced rhTRIM5a sensitivity, even though many of
these did have associated fitness defects. Notably, V86E and I91T
emerged from both adaptation and the random mutant library
screening approaches. Interestingly, however, the random muta-
genesis screen identified several mutations that did not arise
during adaptation yet exhibited reduced sensitivity to rhTRIM5a
without an obvious fitness cost (e.g. V83M and M10L).
Nevertheless, a drawback of random mutant screens is that only
a limited number of mutants can be individually tested. Indeed,
two amino acid substitutions emerged during in vitro evolution that
were not represented in the random mutant library (G116E and
I91N). Additionally, because the experiments were done in human
cells, a potential limitation of both the random mutant library
screening and the in vitro evolution strategies was the possibility
that some rhTRIM5a-resistant mutants could be missed if they
simultaneously caused gain of sensitivity to endogenous human
TRIM5a.
Overall, however, the application of both approaches and
assortment of the resulting mutants in an assisted evolution
approach led to derivation of fit, rhTRIM5a-resistant CA
sequences. Even then, further de novo mutations of the assorted
variant pool was required to generate the optimally resistant CA
sequences. One possible reason for the eventual success of our
approach is that the second round of selection was performed
using a population of CA sequences that was highly enriched for
mutations conferring partial TRIM5a resistance. This population
contained individual mutant assortants that are highly unlikely to
have occurred by chance through the standard approaches to viral
evolution that were attempted initially.
Figure 8. HIV-1 replication in rhesus macaque PBMC. Simian tropic (st) HIV-1 viral stocks encoding SIVmacVif, and either SIVmac239 CA, WT HIV-
1NL4-3 CA, or the indicated mutant HIV-1 CA proteins were normalized according to reverse transcriptase activity and used to infect rhesus macaque
PBMC. Viral replication was monitored by measuring the level of reverse transcriptase in the culture supernatant at the indicated times. The two
charts show replication assays conducted using PBMC from two different macaque donors.
doi:10.1371/journal.ppat.1003667.g008
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Clearly, each individual mutation identified by either adapta-
tion or random mutant screening approaches enabled only a
partial evasion of rhTRIM5a (Figures 2 and 3). These mutations
were distributed over several determinants on the surface of the
HIV-1 capsid, as has been found in previous studies of retrovirus
sensitivity to TRIM5a [40,41,44–47]. Indeed, although the
cyclophilin-binding loop was featured prominently as a site at
which mutations conferring decreased HIV-1 sensitivity to
rhTRIM5a occurred (positions L83, V86, I91, A92, M96), other
determinants included the N-terminal b-hairpin (M10) and helix 6
(G116). One reasonable interpretation of these data is that several
different sites on the capsid exterior contribute to the binding
interaction with TRIM5a, and that mutations at any one of these
sites, reduces, but does not eliminate interaction. Interestingly, a
comparison of the distribution of mutations in MLV CA and HIV-
1 CA that arose during the selection of rhTRIM5a-resistant viral
variants [47] reveals striking similarity (Figure S9A and S9B). A
key difference, however, is that single amino acid substitutions in
MLV CA conferred near complete resistance to rhTRIM5a [47],
while multiple substitutions were required in HIV-1 to achieve the
same effect. Perhaps the viral challenges to which rhTRIM5a has
been subjected to during its evolutionary history have shaped it in
such a way that it is a more robust inhibitor of lentiviruses than
gammaretroviruses.
Because mutations in the cyclophilin-binding loop of HIV-1 CA
have previously been shown to reduce the contribution of CypA to
rhTRIM5a activity [61,62], it is possible that perturbation of
CypA binding may have contributed to the acquisition rhTRIM5a
resistance described herein. Although retention of sensitivity to
restriction by TRIM-Cyp suggests that CypA binding has been
retained in the mutants described herein (Figure 7B), it remains
possible that the role of CypA in rhTRIM5a activity was
perturbed. Indeed previous work has suggested that a V86M CA
mutation, while not preventing CypA binding, eliminates the
contribution of CypA to the restriction of HIV-1 by huTRIM5a
mutants [63]. It therefore remains unclear whether cyclophilin-
binding loop mutations in rhTRIM5a-resistant capsids have
altered the involvement of CypA in restriction or simply decrease
the binding of rhTRIM5a to HIV-1, independent of CypA.
Although HIV-1 CA mutations could be combined to give near
complete escape from restriction, some combinations, particularly
those derived from the first round of selection, were apparently
deleterious to viral fitness. The need to alter multiple determi-
nants, coupled with the inherent genetic fragility of HIV-1 CA
[48] likely underlies the difficulty in generating combinations of
CA mutations that confer rhTRIM5a resistance while maintaining
high fitness. It is possible that the LNEIE and INEIE mutants,
which were both fit and resistant to restriction by rhTRIM5a,
include compensatory changes that alleviate fitness costs that
accompanied escape from rhTRIM5a restriction. Our group has
recently demonstrated that about 70% of randomly introduced
single amino acid substitutions, and nearly all two-amino acid
substitutions in CA are lethal to HIV-1 [48]. This lack of
robustness in CA is also evident in MLV, as the N-terminal
domain of MLV CA, unlike other regions of Gag, is intolerant of
small insertions [64]. In the case of HIV-1, most lethal CA
mutations were shown to disrupt normal particle formation [48].
However, interactions with multiple host factors, or structural
requirements that dictate proper disassembly may also decrease
the genetic robustness of CA. Thus, mutants containing combi-
nations of changes required to both escape rhTRIM5a and retain
fitness should be very rare, and this may be one reason why
evolution has selected CA as a target for host antiviral proteins.
Notably, the incomplete escape that was evident in viral
populations derived from initial selection experiments included a
double amino acid mutant (NE), which was both fit and
incompletely resistant to restriction in MT2-rhTRIM5a cells, as
well as mixtures of viruses containing WT and mutant codons
at V86 and G116. Although a V86E/G116E double mutant
clearly had the opportunity to dominate in these cultures, it
exhibited a clear loss of fitness, probably explaining why it did not.
While it is formally possible that the fitness defect in V86E/G116E
and other unfit rhTRIM5a-resistant mutants is species-specific
and would not exist in monkey cells, we consider this unlikely,
given that low infectiousness was also observed in hamster cells
(Figure S2).
Importantly, mutations conferring resistance in rhTRIM5a-
expressing cell lines allowed HIV-1 encoding SIVmac239 Vif to
replicate in PBMC from rhesus macaques. Indeed, an HIV-1
encoding the LNEIE mutant CA protein replicated as well as or
better than a virus encoding an SIVmac239 CA protein, suggesting
that TRIM5a activity was entirely bypassed. Therefore, the HIV-
1 CA mutations identified here enable HIV-1 to overcome the
species-specific tropism barrier imposed by rhTRIM5a. Thus,
although the barrier to the evolution of fit, rhTRIM5a-resistant
HIV-1 CA proteins is apparently high, it is not insurmountable.
Moreover, although the two amino acid NE mutant was inferior to
the 5 and 6 amino acid CA mutants, in that it retained some
degree of sensitivity to rhTRIM5a in human cell lines, the NE
mutant replicated well in rhesus PBMC, and had little if any ability
to saturate rhTRM5a in the FRhK cell line. Thus, one caveat that
should be attached to the above discussion is that the level of
rhTRIM5a expression in the engineered human cell lines in which
our selection experiments were performed likely exceeds the
endogenous levels present in rhesus macaque cells. The number of
mutations required to operationally escape TRIM5a inhibition in
a natural setting may therefore be fewer than is suggested by our
studies. In any case, the CA mutants identified herein should
facilitate the development of rhesus macaque-based non-human
primate models of HIV-1 infection.
Materials and Methods
Cell lines and viruses
Primate adherent cells (293T and FRhK-4) and suspension cells
(MT2, MT4, CEM, and rhesus macaque PBMC) were cultured in
DMEM and RPMI, respectively. CHO K1-derived pgsA-745 and
the previously described pgsA-rhTRIM5a and pgsA-omkTRIM-
Cyp cell lines [30] were maintained in Ham’s F12 media with
1 mM L-glutamine. All growth media was supplemented with
10% fetal bovine serum and gentamicin.
Human T-cell lines (MT2, MT4 and CEM) expressing
rhTRIM5a were prepared by transduction with a murine
leukemia virus (MLV) vector containing rhTRIM5a cDNA,
inserted 59 to an internal ribosomal entry site and a blasticidin
resistance gene. The rhTRIM5a cDNA was previously cloned
from FRhK-4 cells [3] and the sequence matches allele 3, as
described by Lim et al [65]. This rhTRIM5a allele belongs to a
class of rhTRIM5a alleles that encode TFP at amino acid residues
239–241 and restrict HIV-1 more potently than other alleles
[54,55]. To generate the cell lines, 293T cells were cotransfected
using polyethyleneimine (PolySciences) as previously described [7]
with 100 ng of a vesicular stomatitis virus G protein (VSV-G)
expression plasmid, 500 ng of a MLV GagPol expression plasmid,
and 500 ng of the rhTRIM5a-expressing MLV vector. The
resulting virus was used to transduce MT2, MT4, or CEM cells.
Cells were selected with 10 mg/mL blasticidin and single-cell
clones expressing rhTRIM5a were derived by limiting dilution.
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The replication competent HIV-1/GFP used in viral evolution
experiments and for measurements of rhTRIM5a sensitivity was
produced by transfection of an HIV-1NL4-3/HIV-1HXB2 recombi-
nant proviral plasmid that encoded GFP in place of Nef (pNHG,
GenBank accession number: JQ585717) [66]. Infectious titer was
determined by inoculating MT2 cells (26104 per well) in 96-well
plates with 50 mL of serially diluted supernatant. After allowing
infection to proceed overnight, further replication was blocked by
the addition of 100 mg/mL dextran sulfate. Two days after
infection, cells were fixed in 2% paraformaldehyde and the
number of infected cells enumerated by FACS.
Viruses used to saturate rhTRIM5a in FRhK-4 cells were
prepared by cotransfection of 293T cells with pCRV1-HIV-1NL4-3
GagPol (WT or rhTRIM5a-resistant mutant), the HIV-1 based
vector pV1, which lacks a reporter gene, and a VSV-G expression
plasmid at a 5:5:1 ratio, respectively [16]. Titers were determined
using TZM-bl indicator cells, infected colonies were stained and
counted using X-Gal two days post-infection. The reporter virus
used to test for rhTRIM5a saturation in FRhK-4 cells, the viruses
used for the biochemical analysis of core components, and the
viruses used to infect pgsA-745 cell lines were produced in the
same manner, except an HIV-1 based vector encoding GFP
(pCSGW) [67] was used instead of pV1. VSV-G enveloped N-
MLV was also produced in the same manner, except N-MLV
GagPol expression plasmid and an MLV based vector encoding
GFP (pCNCG) were used [68].
Virus evolution in rhTRIM5a expressing cells
Prior to inoculation of MT2 and MT4 cells expressing
rhTRIM5a, a cloned pNHG-derived virus that lacked Vpr was
allowed to replicate in MT2 cells to generate sequence diversity.
Specifically, 56105 MT2 cells were infected with NHG at an MOI
of 0.001. To maintain a viable cell population (the culture would
have otherwise died due to cytopathic effects) and expand the viral
population, uninfected MT2 cells were added as follows: 56105
cells at 4 dpi, 106 cells at 6 dpi and 8 dpi, 36106 cells at 10 dpi, and
46106 cells at 13 dpi. After 15 days of replication, cell-free
supernatant was harvested and titrated on MT2 cells. Thereafter,
1.256106 IU were used to infect two cultures of 56106 MT2-
rhTRIM5a cells, two cultures of MT4-rhTRIM5a cells, and one
culture each of MT2 and MT4 cells transduced with empty vector.
Cells were diluted to 35 mL after an overnight infection in 5 mL.
To measure the initial infection, dextran sulfate was added to a
100 mL aliquot of cells one day after infection, which were then
fixed the following day. To monitor the spreading infection, 100 mL
aliquots of cells were fixed periodically in 2% paraformaldehyde
and the fraction of infected (GFP positive) cells determined by
FACS analysis. After cytopathic effects became abundant in the
culture, and/or the percentage of infected cells had peaked, 2 mL
cell-free supernatant was used to infect 56106 fresh cells as before.
However, beginning with the fifth passage in MT2- rhTRIM5a cell
lines and the fourth passage in MT4- rhTRIM5a cell lines 5 mL of
supernatant was used to initiate new passages.
To recover CA sequences from viruses replicating in
rhTRIM5a expressing cells, DNA was isolated from infected cells
using the Qiagen DNeasy Blood and Tissue Mini Kit and
sequences encoding CA were amplified using PCR and a sense
primer, 59-AAGGAAGCCTTAGATAAGATAGAGG-39 along
with an antisense primer 59- TTGCCTTTCTGTATCATTA
TGGTAG -39. Products were directly sequenced, without cloning,
using the sense primer. To generate proviral clones containing
adapted CA sequences, PCR amplification was done using primers
59-GCACAGCAAGCGGCCGCTGACACAGG-39 and 59-GCC
AAAACGCGTGCTTTATGGCCGGG-39 to add NotI and
MluI restriction sites for insertion into a pNHG derivative that
was engineered (by silent mutagenesis) to contain NotI and MluI
restriction sites flanking CA (GenBank accession number
JQ686832). Additional combinations of mutations were intro-
duced into CA by PCR-based mutagenesis methods as previously
described [69]. For follow-up studies of CA mutants, virus stocks
were generated by transfection of 293T cells with 1 mg proviral
plasmid/well in a 24-well plate. Reverse transcriptase in culture
supernatants was quantified by a previously described assay based
on real-time PCR [70], and infectious titers were determined as
described above. Some CA mutant viruses were also used in
spreading replication experiments, in which 26105 MT2-
rhTRIM5a cells or empty vector transduced MT2 cells in 12-
well plates were infected at an MOI of 0.002. Culture volumes
were kept at 1 mL throughout the experiment. One day after
infection, a 100 mL aliquot of cells was treated with 100 mg/mL
dextran sulfate and fixed the following day to measure the initial
infection. Beginning two days after infection, 100 mL aliquots of
cells were fixed daily for quantitation of GFP positive cells by
FACS analysis.
Screen of random HIV-1 CA mutants for rhTRIM5a
resistance
The construction and analysis of a library of pNHG clones
encoding PCR-mutagenized CA sequences has been previously
described [48]. Briefly, the mutagenized CA library was generated
using the Genemorph II random mutagenesis kit (Agilent) using
the following oligos 59-GTA AGA AAA AGG CAC AGC AAG
CGG CCG CTG -39 and 59- CTT GGC TCA TTG CTT CAG
CCA AAA CGC GTG-39. The PCR template was a pNHG
derivative (JQ686832) that contained silently mutated sequences to
generate NotI and MluI sites flanking CA-encoding sequences
(pNHGCapNM). The PCR product was cloned using a TOPO
TA Cloning Kit and plasmid DNA was extracted from approx-
imately ,16104 pooled, insert-positive colonies. After sequencing
the amplicon from 20 clones to obtain a preliminary estimate of
the mutagenesis frequency, this pooled plasmid DNA was digested
using NotI and MluI and the CA-library insert subcloned into
pNHGCapNM. Proviral plasmid DNA was extracted from
individual cultures derived from 1056 colonies and subjected to
sequencing and further analysis. Ninety-one of the resulting
proviral plasmids that yielded infectious virions were screened for
mutations that decrease sensitivity to restriction by rhTRIM5a.
Specifically, viral stocks containing WT NHG or each of the 91
CA mutants were prepared by transfecting 2.56104 293T cells/
well with 100 ng of pNHG and polyethylenimine in a 96-well
plate. Thereafter, MT2-rhTRIM5a cells or MT2 cells transduced
with empty vector were infected with 2 mL filtered virus in a 96-
well plate at 26104 cells/well. Virus replication was limited to a
single cycle by adding 100 mg/mL dextran sulfate after an
overnight infection. Two days after infection, cells were fixed in
2% paraformaldehyde and subjected to FACS analysis. Stocks of
22 mutants that infected at least 0.1% MT2-rhTRIM5a cells and
were restricted by less than 50-fold (see results) were prepared
again by transfecting 26105 293T cells with 1 mg pNHG in a 24-
well plate. Again, single-cycle infections were done in MT2-
rhTRIM5a cells or MT2 cells transduced with empty vector, using
50 mL of serially diluted supernatant.
Construction and evolution of a library of synthetic CA
sequences containing mutant assortments
To construct a library of CA sequences containing random
assortments of CA mutations (M10L/V, L83M, V86E, H87Q,
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I91N/T, R100S, A105T, and G116E), ten overlapping oligonu-
cleotides, four containing degenerate nucleotides, were used in a
PCR-based gene synthesis to produce a 400 base pair DNA
encoding the 59 portion of CA that included all of the mutated
positions. The heterogeneous gene synthesis product was designed
to encode WT or mutant amino acids at a 1:1 ratio, or a 1:1:1
ratio in cases where two mutations were included at a single
position. Specifically, a 50 mL PCR reaction contained 3 pmol of
each oligonucleotide and gene synthesis was carried out for 20
cycles using Phinzymes Phusion (1 min. 98uC, 1 min. 50uC, and
2 min. 72uC). Thereafter, 2 mL of crude gene synthesis product
was used as template in a 50 mL PCR reaction with 200 nM
external primers (1 min. 98uC, 1 min. 55uC, and 2 min. 72uC)
and the resulting product was gel-purified. The 59 end of the gene
synthesis product was designed to contain a Not I restriction site
while the 39 end was designed to overlap with a second amplicon
that was used to extend the synthetic CA sequence to include the
39 portion of CA and an MluI restriction site. The two overlapping
DNAs were used together as templates for a final PCR, which
produced a DNA that was gel purified, and inserted into pNHG.
Proviral plasmid DNA was purified from 2.56103 pooled bacterial
colonies and 5 mg of this DNA was used to transfect 293T cells.
The resulting virus was used to infect 56106 MT2-rhTRIM5a
cells at an MOI of 0.005. Then, 1 mL of cell-free virus was used in
a second passage onto MT2-rhTRIM5a cells and 100 mL was
used in all subsequent passages. Following 11 passages in MT2-
rhTRIM5a cells, 2 mL of cell-free supernatant was used for serial
passaging in CEM-rhTRIM5a cells.
Biochemical analysis of retroviral cores
Biochemical analysis of retroviral cores in infected cells was
done as previously described [30]. Briefly, pgsA745 cells or its
derivative stably expressing rhTRIM5a were plated in 10-cm
dishes one-day before infection. Cell culture supernatants
containing VSV-G pseudotyped HIV-1NL4-3 GagPol/CSGW
viruses were filtered and treated with RNase free DNaseI (Roche)
at a concentration of 1 unit/ml for 1 hour at 37 uC in the presence
of 6 mM MgCl2. Cells were washed with ice-cold phosphate-
buffered saline (PBS) and 7 ml of chilled virus (with 20 mM
HEPES) was added to the cells at an MOI of ,0.01. After
allowing virus to bind to cells for 30 minutes at 4uC, the inoculum
was removed and cells were washed three times with PBS. Cells
were then incubated at 37uC for 2 hours in complete cell culture
media. Cells were collected in PBS-EDTA, pelleted, and
resuspended in 1 ml of hypotonic buffer (10 mM Tris-Cl
pH 8.0, 10 mM KCl, 1 mM EDTA) supplemented with complete
protease inhibitors (Roche) and SuperaseIN (Life Technologies).
After incubation on ice for 15 minutes, the cell suspension was
dounce homogenized for 50 strokes, using pestle B. Nuclear
material was pelleted by centrifugation at 10006g for 5 minutes
and post-nuclear supernatant was layered on top of a 10–50% (w/
v) linear sucrose gradient prepared in 1X STE buffer (100 mM
NaCl, 10 mM Tris-Cl pH 8.0, 1 mM EDTA). Samples were
ultracentrifuged using a SW50.1 rotor at 30000 rpm for 1 hour.
Ten 500 ml fractions from the top of the gradient were collected,
and proteins and DNA in each fraction were analyzed as
previously described [30].
Virus replication in rhesus macaque PBMC
Rhesus macaque PBMC were stimulated with 3 mg/mL
staphylococcus enterotoxin B (SEB) for three days and 5% IL-2
(Hemogen) throughout the experiment. Following SEB stimula-
tion, PBMC were infected with stHIV-1, which is a chimeric HIV-
1NL4-3 –derived virus in which the Env protein is derived from
SHIV/KB9 and the Vif protein is replaced by that of SIVmac239.
Additionally, stHIV-1/S-CA encodes an SIVmac239 CA sequence
[39,49]. Mutant HIV-1NL4-3 CA sequences were transferred from
NHG to stHIV-1, using BssHII and AgeI restriction sites. Virus
stocks were normalized for reverse transcriptase activity and 16105
PBMC were infected in a 96-well V-bottom plate with inocula
containing 20 pg reverse transcriptase. Following overnight infec-
tion, cells were washed three times and supernatant from the third
wash was frozen for RT quantitation (this value is plotted as 1 day
after infection). After washing, cells were transferred to a 96-well U-
bottom pate. At days 2, 3, 5, 7, 9, 11, and 14 after infection 80% of
the cell supernatant was frozen for RT quantitation and replaced
with fresh medium. For rhTRIMa genotyping, DNA was isolated
from PBMC from both donors using the QIAGEN DNeasy Blood
& Tissue Mini Kit. RhTRIMa exon 8 was amplified by PCR using
sense primer 59- TTGATGTGACACTGGCTCCAAACAAC-39
and antisense primer 59-TGGGTAAAGCGGCCGCCAGAGC
TTG-39. The PCR products were cloned using the Invitrogen Zero
Blunt TOPO PCR Cloning Kit.
Supporting Information
Figure S1 Replication of HIV-1 carrying combinations of
CA mutations that reduce sensitivity to rhTRIM5a. NHG
(WT) or NHG derivatives carrying the indicated mutations were
used to infect MT2-vector (open symbols) or MT2-rhTRIM5a#8
(filled symbols) cells. All infections were done at an equivalent MOI.
To monitor the spreading infections, aliquots of cells were fixed
daily for FACS analysis. The percentage of cells expressing GFP is
plotted against the number of days after infection.
(TIF)
Figure S2 Attenuated CA mutants did not acquire
sensitivity to human TRIM5a. PgsA-745 cells (open symbols)
or pgsA-745 cells stably expressing human TRIM5a (filled
symbols) were infected with VSV-G pseudotyped virions that
carried a GFP-reporter gene and WT or mutant CA sequences in
the context of HIV-1NL4-3 GagPol, as indicated. A VSV-G
enveloped virus carrying N-tropic MLV GagPol and a GFP-
reporter gene was also included as a positive control for human
TRIM5a activity. The infectious titers on each cell line are plotted
(circles, referencing the left Y-axis) and the ratio of the titers is
shown as fold restriction (triangles, referencing the right Y axis).
(TIF)
Figure S3 Vertical mutagenesis at positions where
mutations arose during passage in rhTRIM5a-express-
ing cells. (A–C) MT2-vector (open symbols) or MT2-
rhTRIM5a#8 (filled symbols) were infected with WT NHG or
NHG encoding the amino acids indicated on the X axis at
positions V86 (A), I91 (B) or G116 (C). Each mutant encoded a
single amino acid substitution, and the panel covered each of the
19 possible amino acid substitutions at each position. Infectious
titers (circles, referencing the left Y-axis) and the ratio of the titers
(fold restriction, red triangles referencing the right Y-axis) are
plotted. WT NHG is the leftmost data point on each chart.
(TIF)
Figure S4 Some mutations at CA positions V86, I91 and
G116 have modest effects on sensitivity to human
TRIM5a. (A–C) PgsA-745 cells (open circles) or pgsA-745 cells
stably expressing human TRIM5a (filled circles) were infected
with VSV-G pseudotyped virions that carried a GFP-reporter
gene and HIV-1NL4-3 GagPol encoding WT or mutant CA
sequences. Amino acid substitutions at positions V86 (A), I91 (B),
or G116 (C) are indicated on the X axis as in Figure S2. Infectious
Rhesus Macaque TRIM5a-Resistant HIV-1
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titers on each cell line (circles, referencing the left Y-axis) and the
fold difference in the two titers (triangles, referencing the right
Y-axis) are plotted. N-MLV was included as a positive control
for restriction (C, rightmost data point).
(TIF)
Figure S5 Resistance to rhTRIM5a in spreading repli-
cation assays. NHG (WT) or NHG derivatives carrying the
indicated mutations were used to infect MT2-vector (open
symbols) or MT2-rhTRIM5a#8 (filled symbols) cells at the same
MOI. To monitor the viral spread, aliquots of cells were fixed
daily for FACS analysis. The percentage of infected (GFP positive)
cells is plotted against the number of days after infection.
(TIF)
Figure S6 The CsA-dependent phenotype exhibited by
the A92E CA mutant is not exhibited by the LNEIE,
LMNEIE, or INEIE CA mutants. VSV-G pseudotyped NHG
encoding WT or mutant CA sequences was used to infect HeLa
cells in the absence (open symbols) or presence (filled symbols) of
5 mMCsA, as previously described [57]. The percentage of infected
(GFP positive) cells is plotted versus the volume of each inoculum.
(TIF)
Figure S7 Infectivity of NE, LNEIE, LMNEIE, and
INEIE CA mutants in pgsA-rhTRIM5a cells. PgsA-745
(left) or pgsA-rhTRIM5a cells (right) were infected with VSV-G
pseudotyped virions that carried a GFP-reporter gene and
HIV-1NL4-3 GagPol encoding WT or the indicated mutant CA
sequences. The percentage of GFP positive cells is plotted for each
virus dose.
(TIF)
Figure S8 Infectivity of NE LNEIE, LMNEIE, and INEIE
CA mutants in FRhK-4 cells. VSV-G pseudotyped virions that
carried a GFP-reporter gene and HIV-1NL4-3 GagPol encoding
WT or the indicated mutant CA sequences were used to infect
FRhK-4 cells. The percentage of cells infected (GFP positive) is
plotted as a function of virus dose.
(TIF)
Figure S9 A comparison of the distribution of muta-
tions in MLV CA and HIV-1 CA that reduce sensitivity to
rhTRIM5a. (A) Positions of amino acid residues mutated in the
best performing HIV-1 CA mutant (LNEIE: M10, I91, A92,
M96, G116) are indicated in green on the HIV-1NL4-3 capsid
hexameric structure. (B) Positions of individual amino acid
residues that confer complete resistance to rhTRIM5a (L10,
H114, E92) [47] are indicated on the MLV CA NTD hexameric
structure.
(TIF)
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